(Video) Bloomberg TV: Why is the peptide sector under scrutiny on the eve of the FDA meeting?

This video delves into the current state and future development of the U.S. peptide drug market. With the FDA about to hold an important meeting to review relevant policies, the peptide track is expected to achieve regulatory easing, driving explosive growth in market size. At the same time, peptide products lacking patent protection are causing shocks within the industry, prompting large pharmaceutical manufacturers and compounding pharmacies to reassess their market strategies. Overall, peptide drugs are at the forefront of medical innovation, and their development trends are worth continuous attention.$Hims & Hers Health(HIMS.US)